Desiree Sainthrope is a preeminent legal expert whose career has been defined by navigating the intricate intersection of international trade law and domestic regulatory policy. With a wealth of experience in drafting and analyzing the fine print of high-stakes trade agreements, she has become a leading voice on global compliance, particularly in how frameworks like the USMCA reshape local industries. Her deep-seated expertise in intellectual property and the legal ripples caused by emerging technologies allows her to dissect complex legislative shifts with surgical precision. In this conversation, we explore the transformative 2026 reforms in Mexico, where a revamped IP landscape is forcing pharmaceutical innovators and regulatory bodies into a new era of accountability and strategic complexity.
The discussion centers on the sweeping legislative changes that took place in April 2026, specifically targeting the Federal Law for the Protection of Industrial Property and Health Law Regulations. We delve into the mechanics of patent-term compensation for administrative delays, the introduction of formal regulatory data protection for the first time in decades, and the evolving role of patent linkage between Mexico’s sanitary and industrial property authorities. The expert also addresses the lingering ambiguities regarding biologics and orphan drugs, the procedural tightropes companies must walk to secure their exclusivity, and the crucial role that strategic litigation will play as these new rules are tested in real-world scenarios.
The 2026 amendments to Mexico’s Federal Law for the Protection of Industrial Property have fundamentally altered how patent holders are compensated for administrative delays; could you walk us through the mechanics of this new system and how it addresses the gaps left by previous legislation?
The legislative shifts we saw on April 3, 2026, were nothing short of a seismic event for the innovative sector in Mexico, as they finally breathed life into Article 136bis. For years, there was a palpable sense of frustration among patent holders who watched their 20-year exclusivity windows evaporate while waiting for the Federal Commission for the Protection against Sanitary Risks, or COFEPRIS, to process marketing authorizations. Under the new rules that entered into force on April 4, 2026, a structured relay race begins where COFEPRIS is now mandated to notify the Mexican Institute of Industrial Property, IMPI, of any unreasonable delays, which triggers a compensatory period. The patent holder then has a strictly defined 60-business-day window following the grant of the marketing authorization to file their request, ensuring that the lost time is recaptured through a complementary certificate. This mechanism specifically targets allopathic medicines and caps the extension at five years, finally aligning Mexico with the commitments made under Article 20.46 of the USMCA. It feels like a long-overdue professionalization of the process, replacing the previous “legal vacuum” with a clear, albeit rigorous, timeline that rewards those who stay on top of their regulatory filings.
Given that COFEPRIS handles health risks and IMPI manages industrial property, how do you see the collaboration between these two historically distinct entities evolving under the new mechanism for patent-term extensions?
The relationship between these two agencies is moving from a distant professional courtesy to a high-stakes partnership, though it is not without its growing pains. We are currently witnessing a fascinating, and at times stressful, experiment in inter-agency cooperation where the health authority, which lacks patent expertise, is tasked with identifying delays that impact IP exploitation. The Decree states that COFEPRIS must decide on the compensation and inform IMPI, but the lack of granular formulas in the initial drafting has created a heavy reliance on the secondary regulations expected within 180 days of the April 25, 2026, enforcement. For legal teams, the sensory experience of this process is one of intense scrutiny; you have a single, five-working-day opportunity to correct any deficiencies in your request before it is dismissed entirely. This “one-shot” rule creates a high-pressure environment where every document must be pristine, as the coordination between a scientific regulatory body and a legalistic IP office leaves very little room for administrative error or interpretive nuance.
For the first time since the mid-90s, Mexico has introduced formal provisions for regulatory data protection; how does this five-year window change the strategic calculus for companies launching allopathic medicines?
This is perhaps the most significant “quiet” victory for innovators since the original NAFTA went into effect in 1994. Previously, obtaining data exclusivity was a grueling marathon through the court systems, often requiring years of litigation to protect the safety and efficacy data that cost millions to generate. Now, the Health Law Regulations provide an automatic five-year shield for this information, meaning that generic applications cannot rely on an innovator’s clinical trials without express written consent. It’s a massive relief for companies because COFEPRIS now informs the marketing authorization holder of this protection the moment the authorization is granted, effectively baking exclusivity into the administrative birth of the product. However, there is a lingering shadow of uncertainty regarding the “new molecule definition” and how it applies to things like new indications or biologics, which means that while the floor of protection has been raised, the ceiling for more complex developments remains a bit hazy and will likely require further judicial testing.
The patent linkage system has seen its share of friction, particularly with the new opposition mechanism; in your view, what are the primary hurdles patent owners face when trying to intervene in generic or biosimilar applications?
The primary hurdle is the informational “black box” that patent holders must navigate when a potential competitor enters the fray. Since June 2025, COFEPRIS has been required to publish a list of generic and biosimilar applications, but the data disclosed is often so sparse that it feels like trying to identify a ship in a thick fog. A patent owner has a mere 10 working days from the publication of that list to file an opposition, which is an incredibly tight turnaround for a team to analyze the potential infringement and draft a technical response. Once that opposition form is submitted, the patent holder is essentially sidelined; they aren’t involved in the subsequent technical collaboration between IMPI and COFEPRIS, which can feel incredibly disempowering. This lack of a robust “due notice” system means that while the 2026 reforms tidied up some technical references to the law, they didn’t quite deliver the transparent, interactive linkage system that many of us hoped would emerge from the USMCA obligations.
With the 2026 reforms still in their infancy, what are the “grey areas” in the legislation that keep you up at night, particularly regarding how “unreasonable delay” is defined or how existing patents are handled?
What keeps me up is the ambiguity surrounding what exactly constitutes a “compensable” delay versus an “applicant-caused” delay. The regulations exclude periods resulting from unsuccessful judicial challenges or force majeure, but the criteria for these assessments remain largely undefined, leaving a lot of discretionary power in the hands of COFEPRIS. There is also the thorny issue of retroactivity; the transitory provisions suggest that procedures initiated before April 4, 2026, follow the old rules, but we are already seeing a case-by-case push to apply the more favorable USMCA-aligned standards to older patents. Furthermore, the exclusion of orphan drugs from the clear-cut definitions applied to allopathic medicines creates a regulatory “no man’s land” for some of the most innovative and needed therapies in the market. It’s a landscape where the broad strokes of the law have been painted, but the fine details that determine millions in revenue are still being sketched out in real-time by administrative practice and the first wave of post-reform litigation.
What is your forecast for the Mexican pharmaceutical market and the evolution of these IP protections over the next five years?
I forecast a period of intense, strategic “regulatory housekeeping” where the most successful companies will be those that integrate their IP and regulatory departments into a single, seamless unit. We are going to see a surge in litigation as the industry tests the limits of the five-year compensation cap and the exact scope of “regulatory data protection” for biologics and new indications. Within the next five years, the “constructive friction” between COFEPRIS and IMPI will likely lead to the creation of more specialized, joint task forces to handle the technical evaluation of patents, moving away from the currently siloed approach. While there will be initial turbulence as the 180-day supplemental regulations are rolled out and challenged, the ultimate result will be a more mature, predictable Mexican market that finally treats pharmaceutical innovation as a long-term investment rather than a regulatory hurdle to be cleared.
